Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Boston Scientific Corporation
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
ViroMissile, Inc.
Eisai Inc.
Jonsson Comprehensive Cancer Center
SAPU NANO (US) LLC
Guerbet
University of Washington
Nantes University Hospital
AccSalus Biosciences, Inc.
Massive Bio, Inc.
Cook Group Incorporated
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
UNICANCER
Travera Inc
Teclison Ltd.
Institut Bergonié
Stanford University
Leiden University Medical Center
Xencor, Inc.
Provectus Pharmaceuticals
Vanderbilt-Ingram Cancer Center
University of Aarhus
SpeciCare
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
Stanford University
INSYS Therapeutics Inc
Delcath Systems Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Tel-Aviv Sourasky Medical Center
Adherex Technologies, Inc.